The GSK BET BD2 inhibitor, GSK852 , is one of a series of BD2-targeting compounds published last month by GSK (see a fragment-based approach here , a DEL screening approach here , and a pincolinamide molecule here ). Each of these campaigns is impressive and educational in different ways, and the collective GSK BD2 effort is a tour de force [...]
< 1 minute read
Dec. 16, 2021
GSK852: a BET BD2 inhibitor
GSK852
1000x BD2-selective BET bromodomain inh. orally available in dog rational design from prior lead Journal of Medicinal Chemistry GlaxoSmithKline, Stevenage, UK